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Background: Limited data exist for the efficacy of second-line antiretroviral therapy among children in resource
limited settings. We assessed the virologic response to protease inhibitor-based ART after failing first-line non-
nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens.
Methods: A retrospective chart review was conducted at 8 Thai sites of children who switched to PI –based
regimens due to failure of NNRTI –based regimens. Primary endpoints were HIV RNA< 400 copies/ml and CD4
change over 48 weeks.
Results: Data from 241 children with median baseline values before starting PI-based regimens of 9.1 years for age,
10% for CD4%, and 4.8 log10 copies/ml for HIV RNA were included; 104 (41%) received a single ritonavir-boosted PI
(sbPI) with 2 NRTIs and 137 (59%) received double-boosted PI (dbPI) with/without NRTIs based on physician
discretion. SbPI children had higher baseline CD4 (17% vs. 6%, p < 0.001), lower HIV RNA (4.5 vs. 4.9 log10 copies/ml,
p < 0.001), and less frequent high grade multi-NRTI resistance (12.4% vs 60.5%, p < 0.001) than the dbPI children. At
week 48, 81% had HIV RNA< 400 copies/ml (sbPI 83.1% vs. dbPI 79.8%, p = 0.61) with a median CD4 rise of 9%
(+7%vs. + 10%, p < 0.005). However, only 63% had HIV RNA< 50 copies/ml, with better viral suppression seen in sbPI
(76.6% vs. 51.4%, p 0.002).
Conclusion: Second-line PI therapy was effective for children failing first line NNRTI in a resource-limited setting.
DbPI were used in patients with extensive drug resistance due to limited treatment options. Better access to
antiretroviral drugs is needed.
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The most commonly used first-line antiretroviral therapy
(ART) in HIV-infected children in resource-limited set-
tings (RLS) is a non nucleoside reverse transcriptase in-
hibitor (NNRTI)-based treatment[1,2]. Data from
individual cohorts in Thailand [3], Uganda [4] Cambodia
[5] and those from a meta-analysis of 1457 children [1]
showed that 70–81% had viral suppression after 1 year
of first-line treatment. Several pediatric programs in RLS
have begun to provide second-line therapy; 5.8% and
20% among cohorts of HIV-infected children in South
Africa [6] and the TREAT Asia regional network [7], but
treatment outcomes data are limited. The second-line
regimen for children failing NNRTI-based treatment in
all treatment guidelines is a low-dose ritonavir boosting
protease inhibitors (boosted PI) in combination with 2
nucleoside reverse transcriptase inhibitors (NRTIs) [8,9]
which was reasonably effective [10].
However, in RLS without routine virologic monitoring,
the diagnosis of treatment failure is usually late, of which
brings about concerns for multi-NRTI resistance [11].
Reported incidence rate of multi-NRTI drug resistance
from cohort with routine viral load monitoring is only
8% [12] compared to 36% seen in settings in which treat-
ment failure was detected by clinical or immunologic
criteria [13]. In such cases in RLS, the only effective
anti-retroviral (ARV) drug option available for second-
line therapy is boosted PI with limited choices for effect-
ive NRTIs. Often times, double-boosted PI regimens are
used to provide 2 active agents in the regimen. Double-
boosted PIs is an alternative second-line therapy option
in the Thai National Guideline; however, there have been
limited data of its safety and efficacy in HIV-infected
children [14].
The primary objective of this study is to describe the
immunologic and virologic efficacy of second-line ARV
regimens containing either single- or double-boosted PI
over a 48-week period in children with NNRTI-based
treatment failure in Thailand.
Material and methods
Study design and subjects
We formed a network of 8 large pediatric HIV centers in
Thailand to retrospectively collect treatment outcome
data of all children who failed NNRTI-based therapy and
received ritonavir-boosted PI regimen as a second-line
drug regimen. Immunologic treatment failure was
defined according to the Thai guideline either CD4 per-
centage decline > 5 percentage point in a patient with
CD4% less than 15, or CD4 cell count drop > 30% of
baseline within 6 months [15]. Before 2006, the access to
plasma HIV RNA monitoring was limited and it was
performed after immunologic failure was suspected.
Virological failure was defined as HIV RNA> 1000copies/ml after at least 6 months of antiretroviral ther-
apy. After 2006, annual HIV RNA was accessible
through the national program. In some cases, genotypic
resistance testing was performed before switching to
second-line regimens, and the test was performed only if
plasma HIV RNA was > 1,000 copies/ml.
Cases selected were HIV-infected children
aged < 18 years, with a documented history of immuno-
logic or virologic failure on NNRTI-based ART who
received ritonavir-boosted PIs-based regimen for at least
24 weeks. They were excluded if they had previously
received PIs treatment prior to the ritonavir-boosted PIs
for longer than 30 days, or received second-line drugs
not belonging to the NRTI, NNRTI, and PI classes. Stan-
dardized forms were used for retrospective hospital chart
extraction: include demographics, CDC HIV clinical
classification, history of ART, CD4 cell count and per-
centage, and genotypic resistance test result before
switching to PI-based HAART. Follow up CD4, plasma
HIV RNA and adverse events after switch to PI regimen
were extracted and censored at last patient visit. After
switching to second-line therapy, CD4 was uniformly
monitored every 6 months and HIV RNA every 6–
12 months. Single-boosted PI was defined as low dose
ritonavir combined with one other PI drug. Double-
boosted PI was defined as low dose ritonavir combined
with another two PI drugs, or therapeutic dose ritonavir
(350–400 mg/m2/dose) combined with one other PI
drug.
The HIV RNA testing was performed using 50 copies/
ml as the limit of detection, except for some cases in the
early 2000s which used 400 copies/ml as the detection
limit. Genotypic resistance testing was performed by
TrueGene HIV-1 Genotyping system (Visible Genetics,
Inc., Toronto, Canada) at 5 sites, ViroSeq HIV-1 Geno-
typing System (Celera Diagnostics, Alameda, Calif.) at 1
site and with an in house method using Stanford and
International AIDS society (IAS) database [16] at 2 sites.
The study was approved by the Ethics Committees at all
sites.
Statistical analysis
Primary endpoints were the proportion of children with
plasma HIV RNA< 400 copies/ml at week 48 and the
CD4 changes at 48 weeks after switching to second-line
PI therapy. Secondary endpoints were the proportion of
children with plasma HIV RNA< 50 copies/ml and the
prevalence of adverse events. The analysis was per-
formed using available data.
The cumulative probability of virologic treatment fail-
ure defined as HIV RNA> 400 copies/ml after at least
6 months of second-line boosted PI regimen was calcu-
lated using the Kaplan Meier estimates. The data
included patients who had HIV RNA result at least once
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or earlier in cases of discontinuation of the follow-up.
The difference between single- and double -boosted PI
was tested using the log rank test.
The predictors for treatment failure defined as HIV
RNA<400 copies/ml at week 48 were explored in a lo-
gistic regression model. Factors included CD4 cell count
at time of switch to boosted PI regimen (dichotomized
as > 100 cells/mm3), plasma HIV RNA at time of switch
to boosted PI regimen (dichotomized as > 10,000 copies/
ml), ART regimen as single-boosted PI or double-
boosted PI, use of lopinavir/ritonavir (LPV/r) –contain-
ing regimen, and grade of resistance mutations. Defin-
ition of high grade multi-NRTI resistance was defined
as ≥ 4 thymidine analog mutations (TAMs) or the pres-
ence of Q151M or 69 insertion. Low grade multi-NRTI
resistance was defined as 1 to 3 TAMs. Factors with p-
value < 0.2 in the univariate analysis were tested in the
multivariate analysis. Analyses were performed using
SAS version 9.1(SAS Institute, Cary, NC, USA).
Results
Patient characteristics and antiretroviral regimen
Between September 2002 and June 2007, 241 children
were enrolled, including 1, 11, 62, 63, 60, and 44 chil-
dren per calendar year. There were 104 children who
switched to single-boosted PI and 137 children who
switched to double-boosted PI (137 children) at 8 HIV
pediatric clinics. The baseline characteristics of the chil-
dren are shown in Table 1. The medians (interquartile
range [IQR]) were 9.1 (7.2-11.1) years for age and 2.2
(1.5-2.9) years for duration of NNRTI-based regimen.
Among 203 children who had genotypic resistance test-
ing performed, 195 children (96%) had the test result
prior to switching to PI-based regimen and the
remaining had the test done on stored samples at a later
date. The ARV regimens were chosen by physician’s dis-
cretion based on ARV treatment history, genotypic re-
sistance pattern (if available), and the availability of ARV
drugs. Indinavir has been available in national program,
since 2002, while LPV/r has been available in national
antiretroviral program since 2005. The median follow-up
time was 26.0 months (IQR 12.7-36.8). Overall, at the
time of switch to second line regimens, the children who
were prescribed single-boosted PI were younger (me-
dian: 8.9 versus 9.4 years, P = 0.046), had a significantly
higher baseline CD4% (17% versus 6%, p < 0.001), a
lower baseline plasma HIV RNA (4.5 log10 versus 4.9
log10 copies/ml; p <0.001), and a lower proportion of
genotypes with multi-NRTI resistance mutation (12.4%
versus 60.5%, p < 0.001) compared with children who
received double-boosted PI regimen.
The single-boosted PI regimens included 55 (53%)
indinavir/r (IDV/r) and 49 (47%) lopinavir/r (LPV/r).The NRTI backbones used were 50 (48%) zidovudine
(AZT) plus lamivudine (3TC), 29 (28%) AZT plus di-
danosine (ddI), 17 (16%) ddI plus 3TC and 8 (8%) mis-
cellaneous. Among children in the double -boosted PI
group, 77 (56%) did not receive any NRTI, 37 (27%)
received 3TC as the only NRTI, and 23 (17%) received
other NRTIs. The double-boosted PI regimens were
LPV/r + IDV in 46 (34%) children, IDV/r +Nelfinavir
(NFV) in 24 (18%), LPV/r + Saquinavir (SQV) in 20
(15%), LPV/r +NFV in 17(12%), IDV+RTV in 16(12%),
IDV/r + SQV in 8 (6%) and other PIs in 6 (4%) children.
Efficacy of second-line boosted protease inhibitor
regimens
At week 24, 223 had CD4 information and 190 had
plasma HIV RNA information. The overall median
(IQR) CD4% change was 5 (1–8) % with more CD4 rise
in children who received double- compared to single-
boosted PI (+5% vs. +4%, p < 0.016). Overall 78%
achieved HIV RNA< 400 copies/ml. The proportion
with HIV RNA< 400 copies/ml was not different be-
tween groups; 80.9% (72/89) in single- vs. 76.2% (77/
101) in double-boosted PI regimens. The proportion with
HIV RNA below 50 copies/ml was 59% overall with a
higher proportion in single- compared to double-boosted
PI groups: 66.7% (58/87) vs. 51.2% (44/86) p = 0.038).
The outcomes at week 48 after initiation of boosted PI
regimens are shown in Table 2. The increase in CD4
percentage was significantly higher among children who
received double-boosted PI. Overall, 81.3% had HIV
RNA<400 copies/ml (single-versus double-boosted PI:
83.1% vs. 79.8%, p = 0.61). Sixty-three percent had
plasma HIV RNA< 50 copies/ml; a higher proportion of
these were children who received single-boosted PI com-
pared with those receiving double-boosted PI (76.6% vs.
51.4%, p = 0.002).
Subgroup analysis was performed for the outcome
HIV RNA< 400 copies/ml at week 48. Among children
in single-boosted PI group, 30/36 (83.3%) of children
who received indinavir/r and 24/29 (82.8%) of children
who received lopinavir/r had undetectable viral load (P-
value 0.655). Among children in double boosted PI
group, 47/57 (82.5%) of children who did not receive
any NRTI and 16/22 (72.7%) of children who received
NRTIs had undetectable viral load (p-value 0.252).
Adverse events
During the follow-up period, there were 31 adverse
events that led to discontinuation or substitution of PI
drugs. The median time of discontinuation or substitu-
tion were 13.3 months (IQR 7.1-26.0) after start PI-
based regimen. There were 20 events for IDV-related
toxicity (13% of children who used IDV)due to nephro-
toxicity (n = 11), hyperbilirubinemia (n = 4), nausea









Gender: Male 117 (49) 55 (53) 62 (45) 0.24
Age, years 9.1 (7.2-11.1) 8.9 (6.1-11.1) 9.4 (7.6-11.2) 0.046
Prior to initiate NNRTI regimen
CDC clinical staging 0.04
N 10 (4.2) 7 (6.7) 3 (2.2)
A 58 (24.3) 29 (27.9) 29 (21.6)
B 113 (47.3) 39 (37.5) 74 (54.8)
C 58 (24.3) 29 (27.9) 29 (21.5)
CD4 percentage 5 (1–10) 3.5 (1–11) 5 (2–10) 0.53
CD4 cell/mm3 109 (27–410) 109 (21–395) 112 (28–413) 0.51
Prior to switch to second-line boosted -PI regimen
Weight for age Z-score −1.7 (−2.1 to −0.9) −1.4 (−1.9 to −0.7) −1.9 (−2.3 to −1.4) <0.001
CD4% (n = 239) 10 (4–18) 17 (7–24) 6 (2–12) <0.001
CD4 cell/mm3 (n = 238) 195 (70–442) 379 (165–659) 123 (38–273) <0.001
HIV RNA, log 10 copies/mL (n = 227) 4.8 (4.3-5.3) 4.5 (3.9-5.1) 4.9 (4.5-5.4) <0.001
Antiretroviral treatment history
Mono/dual NRTI exposure prior
to NNRTI-based regimen
71 (29.5) 23 (22.1) 48 (35.0) 0.03
Duration on NNRTI-based treatment, years 2.2 (1.5-2.9) 2.3 (1.5-3.1) 2.0 (1.4-2.9) 0.04
NNRTI regimen 0.01
Nevirapine 167 (69.3) 81 (77.9) 86 (62.8)
Efavirenz 74 (30.7) 23 (22.1) 51 (37.2)
NRTI-backbone
d4T/3TC 142(58.9) 71 (68.2) 71 (51.8) 0.015
AZT/3TC 60 (24.9) 25(24.0) 35(25.6)
d4T/ddI 17 (7.1) 4 (3.9) 13(9.5)
AZT/ddI 14(5.8) 3(2.9) 11(8.0)
ddI/3TC 8 (3.3) 1 (1.0) 7 (5.1)
Multi-NRTI resistance2 <0.001
No TAMs 45/203(22.2) 38/89 (42.7) 7/114 (6.1)
Low grade multi-NRTI 78/203 (38.4) 40/89 (44.9) 38/114 (33.3)
High grade multi-NRTI 80/203 (39.4) 11/89 (12.4) 69/114 (60.5)
Data are presented in median (IQR) or number (%).
1Single boosted PI regimens include ritonavir-boosted Protease inhibitor plus 2 nucleoside reverse transcriptase. Double-boosted PI regimens included 2 protease
inhibitors plus ritonavir with/without NRTI/NNRTI.
2Definition of multi NRTI resistance: high grade is defined as≥ 4 thymidine analog associated mutations (TAMs) or the presence of Q151M or 69Insertion. Low
grade multi NRTI resistance is defined as 1–3 TAMs and without Q151M and 69insertion.
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(n = 1), hypertriglyceridemia (n = 1); 5 events for full dose
RTV (31% of children who used full dose of RTV) due
to intolerance (n = 3), hyperbilirubinemia (n = 1) and
hypertriglyceride (n = 1); 4 events for NFV (10% of chil-
dren who used NFV) due to intolerance (n = 2), rash(n = 1) and diarrhea (n = 1); 1 event for SQV (4% of chil-
dren who used SQV) due to intolerance and 1 event for
LPV/r (0.8% of children who used LPV/r) due to dyslipi-
demia. Proportion of children with elevated low density
lipoprotein was significantly more in the double-boosted
compared to single-boosted PI groups (Table 2).
Table 2 Outcomes after 48 weeks of boosted protease inhibitor regimens
Outcomes Week 48
Total Single –boosted PI Double-boosted PI P-value
Median (IQR) CD4% 20 (15–26) (n = 200) 24 (18–30) (n = 83) 17 (14–22) (n = 117) < 0.001
Median(IQR) CD4% gain 10(1–7) (n = 199) 7(2–12) (n = 83) 10(6–15) (n = 116) 0.002
% with HIV RNA< 400 copies/ml 81.3 (n = 144) 83.1 (n = 65) 79.8 (n = 79) 0.610
% with HIV RNA< 50 copies/ml 63.0 (n = 138) 76.6 (n = 64) 51.4 (n = 74) 0.002
% with Cholesterol > 200 mg/dl 42.5 (n = 162) 34.3 (n = 70) 48.9 (n = 92) 0.062
% with Triglyceride > 150 mg/dl 62.4 (n = 157) 61.8 (n = 68) 62.9 (n = 89) 0.882
% with Low density lipoprotein > 130 mg/dl 31.8 (n = 88) 16.2 (n = 37) 43.1 (n = 51) 0.007
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The cumulative probability of virologic treatment failure
was analyzed by including data from 199 patients who
had HIV RNA results at least once after 6 months of
boosted PI regimens. The Kaplan Meier estimate is
shown in Figure 1. The cumulative probabilities of hav-
ing HIV RNA> 400 copies/ml at 24 months of treatment
were 0.28 (95% CI 0.19-0.40) for children who received
single-boosted PI and 0. 27 (95% CI 0.18-0.39) for chil-
dren on double-boosted PI, p = 0.813 by log rank test.
Predictors for virologic suppression at week 48 after
boosted PI regimen
The predictors for virologic suppression at week 48 were
explored by multivariate logistic regression analysis as
shown in Table 3. Male, young age and high weight for
age z-score were significantly associated with virologic
suppression. Male had a 2.9 times odds of achieving viral
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Figure 1 Kaplan Meier estimated for time to treatment failure, define
regimen.suppression were more likely in children younger than
9 years (3.6 times odds) and those with weight for age z-
score >−1.7 (4.2 times odds). There was a trend for a
better virologic suppression rate among children who
switched to boosted PI regimen when their CD4 count
was > 100 cell/mm3 or plasma HIV RNA levels < 4 log10
copies/ml but these did not reach statistical significance
(p > 0.05).
Discussion
Our study provides information on outcomes of second-
line ART in NNRTI-failing children as part of a large
multicenter observational study in a RLS. This study
showed good virologic efficacy of second-line boosted PI
regimens with 81% achieving HIV RNA< 400 copies/ml
at 48 weeks of treatment. Children with more advanced
HIV disease were preferentially treated with double-
boosted PI versus single-boosted PI regimens. Both regi-
men types performed equally well in suppressing HIV7 53 49 43 35
08 94 84 72 67
8 12 16 20 24
th since switching to PI
Single-boosted PI
Double-boosted PI
d as HIV RNA > 400 copies/ml, after switching to second line PI
Table 3 The predictors for virological suppression defined as HIV viral load< 400 copies/ml at week 48 of boosted
protease inhibitor-based antiretroviral regimens
Proportion of children with
viral suppression n(%)
Univariate analysis Multivariate analysis
Odd Ratios (95%CI) P-value Odd Ratios (95%CI) P-value
ARV regimens
Single-boosted PI 54/65(83.1%) 1 1
Double-boosted PI 63/79 (79.8%) 0.80 (0.34-1.88) 0.611 0.82 (0.27-2.42) 0.712
Gender
Male 62/69 (89.9%) 3.22 (1.27-8.20) 0.014 2.85 (1.06-7.66) 0.018
Female 55/75 (73.3%) 1 1
Age, years
< 9.1 67/76 (88.2%) 2.68 (1.12-6.46) 0.028 3.60 (1.25-10.36) 0.038
≥ 9.1 50/68 (73.5%) 1 1
Weight for age Z-score
< −1.7 42/59 (71.2%) 1 1
≥ −1.7 64/72 (88.9%) 3.24 (1.28-8.18) 0.013 2.42 (0.85-6.84) 0.097
CD4 at time of switch to second line regimen
< 100 cell/mm3 30/42 (71.4%) 1 1
≥100 cell/mm3 84/99 (84.9%) 2.24 (0.94-5.33) 0.068 2.12 (0.71-6.36) 0.178
Plasma HIV RNA at time of switch
< 4 log10 copies/ml 25/29 (86.2%) 1.53 (0.48-4.86) - -
≥ 4 log10 copies/ml 25/111 (80.4%) 1 0.474
Mono/dual NRTI exposure
Yes 41/50 (82.0%) 1.08 (0.45-2.62) 0.867
No 76/94 (80.9%) 1
Duration on NNRTI-based
< 2.2 year 69/84(82.1%) 1.15 (0.50-2.67) 0.745
≤ 2.2 year 48/60(80.0%) 1
NNRTI –based regimen
NVP-based 81/96 (84.4%) 1.80 (0.77-4.23) 0.178 1.24 (0.43-3.55) 0.691
EFV-based 36/48 (75.0%) 1 1
Multi-NRTI resistance 0.809 - -
No TAMs 25/32 (78.1%) 1
Low grade multi-NRTI 35/44 (79.6%) 1.09 (0.36-3.31)
High grade multi-NRTI 36/43 (83.7%) 1.44 (0.45-4.62)
LPV/r in the regimen
Yes 60/71 (84.5%) 1.53 (0.66-3.58) 0.325
No 57/73 (78.1%) 1
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50 copies/ml was significantly less with double-boosted PI.
This study supports recycling of 2NRTIs in combin-
ation with a potent boosted PI as second-line therapy
in children. The 2010 WHO guideline recommend re-
placing AZT/3TC or d4T/3TC in the first line regimen
with abacavir (ABC)/3TC or ABC/ddI [17]; however,that practice is rare in Thailand due to the high cost of
ABC rendering it unavailable in the Thai national ARV
program. Therefore, recycling of inactive or partially ac-
tive 2NRTIs such as AZT/3TC, AZT/ddI or ddI/3TC
was common in this study. At the time of the study,
tenofovir (TDF) was not yet approved for adolescents
nor was it available in Thailand. Similarly, LPV/r is the
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supply in Thailand before 2005, resulting in the use of a
more toxic drug, IDV, in half of our children.
The virologic response to second-line single boosted
PI regimen in our study compares favorably to reports
from other countries [15-17]. In a French cohort, 92%
on LPV/r second line regimens had HIV RNA< 400 cop-
ies/ml despite having lower CD4 (14.8%) and higher
HIV RNA (4.8 log10 copies/ml) than our children. The
Spanish multicenter retrospective observational study
showed 71.5% of PI-experienced children on LPV/r-
based having HIV RNA<400 copies/ml [10]. A long
term cohort of children treated with LPV/r-based regi-
men showed that 81% remained on therapy after more
than 4 years; 75% of those children had HIV RNA< 400
copies/ml at their last visit. [18] In another pediatric
study, patients tended to have better virologic outcome
if they were on LPV/r as supposed to unboosted PI, nel-
finavir [19]. We also saw a trend towards better virologic
outcome among children who received LPV/r, but this
did not reach statistical significance. In Malawi, 10% of
adults died after initiating second-line regimen and 85%
of the survivors had viral suppression at 12 months [20].
Double-boosted PI is an acceptable alternative second-
line therapy option in Thailand for children with late
treatment failure who have few or no fully active drugs
aside from PIs [15]. The pediatric HIV-NAT 017 study
which treated children with second-line SQV and LPV/r
reported a viral suppression rate similar to that observed
in our study with 64% having HIV RNA< 50 copies/ml
at week 48 [21]. A non-randomized study in Thai adults
showed that the double-boosted PI regimen was not as
potent in suppressing HIV RNA to below 50 copies/ml
when compared to the single-boosted PI regimen among
patients with low grade multi- NRTI resistance muta-
tions [22]. Of note is the inability of that study to com-
pare the two regimen types among patients with high
grade multi-NRTI resistance mutations. Our study
showed that double-boosted PI had a higher rate of low
level viremia, HIV RNA between 50 and 400 copies/ml,
compared to single-boosted PI. This could possibly be
confounded by indication that children with more
advanced disease received double-boosted PI regimen or
due to inferior potency of a PI mono-class regimen. A
recent randomized study of second-line PIs in Thai
adults showed mono LPV/r treatment to result in sig-
nificantly more low level viremia than a 3-drug regimen
with TDF, 3TC and LPV/r [23]. Another second-line
study in Thai adults who received a single active drug,
LPV/r, together with 3TC to reduce viral fitness also
showed that only 67% achieved HIV RNA <50 copies/ml
with 16% having low viremia between 50–400 copies/ml
[24]. The recent review literature [25] and meta-analysis
[26]on protease inhibitor monotherapy also showed aslightly inferior virological efficacy of protease inhibitor
monotherapy than that of protease inhibitor plus
nucleosides. However, failure of protease inhibitor
monotherapy does not imply losing therapeutic options,
usually reintroduction of nucleosides can lead to virolo-
gic suppression. [25,26] The higher rates of dyslipidemia
with double-boosted PI and the higher pill burden fur-
ther limits its use particularly if newer and more potent
ARVs with favorable lipid profile e.g. atazanavir, daruna-
vir, and raltegravir becomes available to children in RLS.
There is a lack of evidence to inform the optimum
time to switch to second line regimens in RLS. The
WHO guideline, relying heavily on a public health ap-
proach to care, recommends switching to second-line
regimen when CD4 is < 100 cells/mm3 or HIV RNA is >
5,000 copies/ml [27]. We demonstrated a trend towards
better virologic suppression following second-line ther-
apy in children who switched when their CD4 was > 100
cell/mm3 or HIV RNA was < 10,000 copies/ml. Delayed
in switching to second-line therapy may lead to resist-
ance mutations accumulation which would be problem-
atic in RLS where ARV options are limited. The
PENPACT-1 study showed that children failing first-line
NNRTI who were randomized to a delayed switch at
HIV RNA> 30,000 copies/ml had more TAMs compared
to those who switched at HIV RNA> 1,000 copies/ml
[28] This however did not affect the overall virologic
outcome after second-line therapy in that study likely
due to several reasons: children who failed had low rates
of NRTI resistance of 1-5%, they had no CD4 failure,
and they had access to routine HIV RNA monitoring,
genotyping and good ARV options. The situation in RLS
may be quite different as switching occurs later with im-
munologic or clinical failure coupled with the lack of
HIV RNA and genotyping monitoring, and limited ARV
options.
This study has several limitations. First is incomplete
data, which is an inherent limitation of a retrospective
study design. The information of adherence to treatment
is not captured. Second, the lack of randomization of
single- versus double-boosted PI regimens hinders the
ability to directly compare the outcome between these
two regimens. Third, the duration of NNRTI-based first
line regimen in our study was relatively short, around
2 years. Furthermore, we have access to laboratory mon-
itoring including CD4, plasma HIV RNA and genotypic
resistance testing to guide the design of the new regi-
mens which may limit the applicability of our results to
other resource-limtted settings where treatment failure
is detected later and genotyping is unavailable. However,
the constraint in available ARV choices in our popula-
tion prohibited us to fully utilize genotyping informa-
tion. Therefore, we believe that our data represent typical
clinical care settings in most resource-limited countries.
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in RLS to give children second-line treatment despite
drug choice and laboratory monitoring constraints. Al-
though we saw a good success rate in our study, one-
fifth did not achieve viral suppression. Such children in
RLS currently have no treatment option beyond second-
line regimens. This emphasizes the urgent need to derive
strategies to study, plan and procure new drugs and drug
classes for children with treatment failure worldwide.
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